Original price was: $75.00.$49.95Current price is: $49.95.
1 in stock
Description
A 100% spore-based, broad-spectrum probiotic shown to maintain healthy gut barrier function. This unique all-spore formula effectively RECONDITIONS the gut by promoting microbial diversity and maintaining key health-promoting, commensal gut bacteria.**
MegaSporeBiotic™ does not require refrigeration and maintains a healthy gut microbiome.**
Start with 1/2 capsule or 1 full capsule with food and slowly increase to 2 capsules per day using the following protocol.
Week 1
1 capsule every other day
Week 2
1 capsule daily
Week 3+
2 capsules daily
If 1 capsule every other day causes side effects, try starting with 1/2 capsules or even 1/4 capsule in some cases. Possible side effects may include abdominal cramping, loose stools, and changes in bowel movements. Though these side effects may be uncomfortable, they are a sign that the product is working! Side effects should resolve within 2-3 days.
** These statements have not been evaluated by the Therapeutic Goods Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Research
MCFARLIN BK, HENNING AL, CARBAJAL KM.
Oral spore-based probiotic supplementation was associated with a reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol. 2017 Aug 15; 8(3): 117–126.
RHEE KJ, SETHUPATHI P, DRIKS A, ET AL.
Role of commensal bacteria in development of gut-associated lymphoid tissue and preimmune antibody repertoire. J Immunol. 2004;172(2):1118-24.
DE PUNDER K, PRUIMBOOM L.
Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front Immunol. 2015;15(6):223.
GONG Y, LI H, LI Y.
Effects of Bacillus subtilis on epithelial tight junctions of mice with inflammatory bowel disease. J Interferon Cytokine Res. 2016;36(2).
SAMANYA M, YAMAUCHI K.
Histological alterations of intestinal villi in chickens fed dried Bacillus subtilis var. natto. Comp Biochem Physiol A Mol Integr Physiol. 2002;133(1):95-104.
TAM NKM, UYEN NQ, HONG HA, ET AL.
The Intestinal Life Cycle of Bacillus subtilis and Close Relatives. Journal of Bacteriology. 2006;188(7):2692-2700.
“SURVIVAL OF PROBIOTICS IN SIMULATED GASTRIC FLUID.”
Food Science Center Report. Silliker Labs. RPN 16663. August 24, 2013.
GIBSON GR, ROUZAUD G, BROSTOFF J, ET AL.
An evaluation of probiotic effects in the human gut: microbial aspects. Final Technical report. FSA project ref G01022.
LEFEVRE M, RACEDO SM, RIPERT G, ET AL.
Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Aging. 2015;12:24.
SERRA CR, EARL AM, BARBOSA TM, ET AL.
Sporulation during Growth in a Gut Isolate of Bacillus subtilis. J Bacteriol. 2014;196(23):4184-4196.
HONG HA, KHANEJA R, TAM NMK, ET AL.
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol. 2009;160(2):134-143.
MANDEL DR, EICHAS K, HOLMES J.
Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1.
MARSEGLIA GL, TOSCA M, CIRILLO I, ET AL.
Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag. 2007;3(1):13-7.
URDACI MC, BRESSOLLIER P, PINCHUK I, ET AL.
Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol. 2004;38(6 Suppl):S86-90.
NISTA EC, CANDELLI M, CREMONINI F, ET AL.
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2004 Nov;20(10):1181-8.
GABRIELLI M, LAURITANO EC, SCARPELLINI E, ET AL.
Bacillus clausii as a Treatment of Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2009;104(5):1327-8.
DI CARO S, TAO H, GRILLO A, ET AL.
Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 2005;17(9):951-60.
CIPRANDI G, TOSCA MA, MILANESE M, ET AL.
Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: A pilot study. Pediatr Allergy Immunol. 2004;15(2):148-51.
Leave a Reply